Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study.

Park DS, Oh JJ, Hong JY, Hong YK, Choi DK, Gong IH, Hwang JH, Kwon SW.

Asian J Androl. 2013 Mar;15(2):249-53. doi: 10.1038/aja.2012.132. Epub 2013 Jan 28.

2.

Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.

Chung BH, Hong SJ, Cho JS, Seong DH.

BJU Int. 2006 Apr;97(4):742-6. Erratum in: BJU Int. 2006 May;97(5):1135.

3.

Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.

Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FM, de la Rosette JJ.

Eur Urol. 2003 Dec;44(6):695-700.

PMID:
14644122
4.
5.

Correlation between serum prostate specific antigen level and prostate volume in a community-based cohort: large-scale screening of 35,223 Korean men.

Park DS, Hong JY, Hong YK, Lee SR, Hwang JH, Kang MH, Kwon SW, Oh JJ.

Urology. 2013 Dec;82(6):1394-9. doi: 10.1016/j.urology.2013.07.071.

PMID:
24295251
6.

Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.

Shim HB, Lee JK, Jung TY, Ku JH.

Prostate Cancer Prostatic Dis. 2007;10(2):143-8. Epub 2007 Jan 2.

PMID:
17199133
7.

[Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].

Bantis A, Zissimopoulos A, Kalaytzis C, Giannakopoulos S, Sountoulides P, Agelonidou E, Voudalikakis C, Touloupidis S.

Hell J Nucl Med. 2007 May-Aug;10(2):138-43. Greek, Modern. Erratum in: Hell J Nucl Med. 2010 Jan-Apr;13(1):78. Soundoulidis, Petros [corrected to Sountoulides, Petros].

PMID:
17684595
8.

Which obesity index best correlates with prostate volume, prostate-specific antigen, and lower urinary tract symptoms?

Yang HJ, Doo SW, Yang WJ, Song YS.

Urology. 2012 Jul;80(1):187-90. doi: 10.1016/j.urology.2012.04.003. Epub 2012 May 23.

PMID:
22626573
9.

Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.

Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C.

Scand J Urol Nephrol. 2003;37(4):322-8.

PMID:
12944191
10.

Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

BJU Int. 2012 Oct;110(7):1023-9. doi: 10.1111/j.1464-410X.2011.10866.x. Epub 2012 Jan 11.

11.

Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.

Bohnen AM, Groeneveld FP, Bosch JL.

Eur Urol. 2007 Jun;51(6):1645-52; discussion 1652-3. Epub 2007 Jan 30.

PMID:
17320271
12.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J.

Urology. 1999 Mar;53(3):581-9.

PMID:
10096388
13.

Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms.

Kayikci A, Cam K, Kacagan C, Tekin A, Ankarali H.

Urology. 2012 Nov;80(5):1088-92. doi: 10.1016/j.urology.2012.08.004.

PMID:
23107399
14.

Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy?

Oh JJ, Jeong SJ, Jeong CW, Byun SS, Hong SK, Choe G, Lee SE.

Prostate. 2013 Jan;73(1):42-7. doi: 10.1002/pros.22537. Epub 2012 May 14.

PMID:
22585359
15.

Effects of obesity on prostate volume and lower urinary tract symptoms in korean men.

Kim GW, Doo SW, Yang WJ, Song YS.

Korean J Urol. 2010 May;51(5):344-7. doi: 10.4111/kju.2010.51.5.344. Epub 2010 May 19.

16.

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.

Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.

PMID:
18817961
17.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J.

J Urol. 2000 Jan;163(1):13-20.

PMID:
10604304
18.
19.

Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology.

Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Söregi S, Madersbacher S.

Urology. 2000 Mar;55(3):397-402.

PMID:
10699620
20.

Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort.

Bhindi B, Margel D, Trottier G, Hamilton RJ, Kulkarni GS, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Toi A, Evans A, van der Kwast T, Fleshner NE.

Urology. 2014 Jan;83(1):81-7. doi: 10.1016/j.urology.2013.07.039. Epub 2013 Sep 14.

PMID:
24044911
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk